A significant shift in the inflammatory disease market is underway as Pfizer's Xeljanz® (tofacitinib) now faces broad generic competition. With discounts reaching…
As a PBM, we closely monitor emerging therapies that have the potential to impact patient outcomes, healthcare costs, and benefit plan strategies. One area generating significant attention right now is the growing interest in peptide therapies…
Federal agencies have released the Affordable Care Act (ACA) and IRS indexed limits applicable to plan years beginning on or after January 1, 2027. Given the significant increase in the ACA Maximum Out-of-Pocket (MOOP) limits for 2027…
Generic tofacitinib (Xeljanz®) has officially entered the market – an important shift in the JAK inhibitor category. With launches across multiple manufacturers…
As biosimilars continue to reshape the market, plan sponsors are looking for real savings – without added complexity. ProAct’s new BioPathways™ Program delivers targeted, clinically-aligned utilization management…
